Amylyx Pharmaceuticals (AMLX) Long-Term Investments (2023)

Amylyx Pharmaceuticals (AMLX) posted Long-Term Investments of $45.0 million for Q4 2023, up 84.79% on a QoQ basis from $24.3 million in Q3 2023.

Analysis

Amylyx Pharmaceuticals (AMLX) Long-Term Investments (2023) Analysis & Trends

Amylyx Pharmaceuticals has reported Long-Term Investments for 1 years, with the latest figure at $45.0 million in Q4 2023.

On a quarterly basis, Long-Term Investments changed N/A year-over-year to $45.0 million in Q4 2023; TTM through Dec 2023 was $45.0 million, a N/A change from a year earlier, with the FY2023 full-year figure at $45.0 million, changed N/A from the prior year.
Long-Term Investments was $45.0 million for Q4 2023 at Amylyx Pharmaceuticals, up from $24.3 million in the prior quarter.
The five-year high for Long-Term Investments was $45.0 million in Q4 2023, with the low at $10.1 million in Q1 2023.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Amgen	212.20 Bn	198.21 Bn	7.24 Bn	-
2	Gilead Sciences	181.83 Bn	178.65 Bn	6.22 Bn	-
3	Vertex Pharmaceuticals	132.47 Bn	124.61 Bn	2.84 Bn	5.79 Bn
4	Regeneron Pharmaceuticals	82.56 Bn	74.56 Bn	3.93 Bn	9.83 Bn
5	Argenx Se	61.59 Bn	56.40 Bn	1.37 Bn	-4.00 Mn
6	Moderna	54.65 Bn	49.51 Bn	52.00 Mn	1.77 Bn
7	Alnylam Pharmaceuticals	34.13 Bn	30.82 Bn	992.69 Mn	22.17 Mn
8	Biogen	31.42 Bn	30.13 Bn	1.96 Bn	-
9	Roivant Sciences	30.21 Bn	30.21 Bn	1.16 Mn	-
10	Amylyx Pharmaceuticals	3.68 Bn	3.68 Bn	-	-

Historic Data

Download Data